Horizon Pharma Proposes To Buy Depomed For $29.25 Per Share
July 07, 2015 at 09:24 AM EDT
After a failed attempt for a takeover in May, Horizon Pharma makes a second proposal to buy Depomed Inc. at a 42% premium of $29.25 per share. With this acquisition, Horizon Pharma would more than double its current approved drug portfolio.
